Log in
RegisterFDA on Truncated AUC [Regulatives / Guidelines]
posted by Helmut 
– Vienna, Austria, 2012-07-25 19:28 (5088 d 21:02 ago) – Posting: # 8982
Views: 3,849
Hi John,
I guess (!!) so.
… because I deleted them in all your previous posts (and this one as well).
❝ The part I am not comfortable about is when FDA stated that "For drugs demonstrating high intrasubject variability in distribution and clearance, AUC truncation warrants caution." Are they referring to highly variable drugs?
I guess (!!) so.
❝ PS. Regarding the multiple blanks in my previous post.... You don't see it now right?
… because I deleted them in all your previous posts (and this one as well).
—
Dif-tor heh smusma 🖖🏼 Довге життя Україна!![[image]](https://static.bebac.at/pics/Blue_and_yellow_ribbon_UA.png)
Helmut Schütz
![[image]](https://static.bebac.at/img/CC by.png)
The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Dif-tor heh smusma 🖖🏼 Довге життя Україна!
Helmut Schütz
The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Complete thread:
- FDA on Truncated AUC jag009 2012-07-25 16:40 [Regulatives / Guidelines]
![[Mix]](https://static.bebac.at/img/mix.png "open in Mix view")
- FDA on Truncated AUC Helmut 2012-07-25 17:01
- FDA on Truncated AUC jag009 2012-07-25 17:19
- FDA on Truncated AUCHelmut 2012-07-25 17:28
- FDA on Truncated AUC jag009 2012-07-25 17:19
- FDA on Truncated AUC Helmut 2012-07-25 17:01
Ing. Helmut Schütz